Literature DB >> 18781310

[Homonymous visual field defect in established migraine with aura].

M Kynigopoulos1, A Tzamalis, T Schlote.   

Abstract

A 48-year-old patient was referred by his general practitioner for opthalmological work-up to clarify sudden onset of a persistent temporal visual field defect of the left eye and a dull headache. Diagnostic testing revealed a cerebrovascular insult with open foramen ovale and migraine with aura. The foramen was successfully closed and resulted in disappearance of the migraine attacks.

Entities:  

Mesh：

Year:  2009        PMID： 18781310     DOI： 10.1007/s00347-008-1818-8

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN： 0941-293X            Impact factor:   1.059


  5 in total

1.  Closure of a patent foramen ovale is associated with a decrease in prevalence of migraine.

Authors:  Martijn C Post; Vincent Thijs; Luc Herroelen; Werner I H L Budts
Journal:  Neurology       Date:  2004-04-27       Impact factor: 9.910

2.  Prevalence of patent foramen ovale in migraine patients with and without aura compared with stroke patients. A transcranial Doppler study.

Authors:  F J Carod-Artal; L da Silveira Ribeiro; H Braga; W Kummer; H M Mesquita; A P Vargas
Journal:  Cephalalgia       Date:  2006-08       Impact factor: 6.292

3.  Closure of a patent foramen ovale: effective therapy of migraine and occipital stroke.

Authors:  Josef Finsterer; Oliver Sommer; Michael Stiskal; Claudia Stöllberger; Helmut Baumgartner
Journal:  Int J Neurosci       Date:  2005-01       Impact factor: 2.292

4.  Secondary prevention after cryptogenic cerebrovascular events in patients with patent foramen ovale.

Authors:  Herwig Walter Schuchlenz; Wolfgang Weihs; Andrea Berghold; Anita Lechner; Reinhold Schmidt
Journal:  Int J Cardiol       Date:  2005-05-11       Impact factor: 4.164

5.  Clinical and imaging findings in cryptogenic stroke patients with and without patent foramen ovale: the PFO-ASA Study. Atrial Septal Aneurysm.

Authors:  C Lamy; C Giannesini; M Zuber; C Arquizan; J F Meder; D Trystram; J Coste; J L Mas
Journal:  Stroke       Date:  2002-03       Impact factor: 7.914
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.